Dr. Reddys Labs launches Paricalcitol Injection in the US market

images-1Dr. Reddys Laboratories, an integrated pharmaceutical company is committed to provide an affordable and innovative medicine for healthier lives. Enhancing its portfolio of products, company has launched Paricalcitol Injection which is the first ANDA product launched in the US market.

Dr. Reddys Paricalcitol Injection is available in:

  • 2 mcg
  • 5 mcg
  • 10 mcg

Paricalcitol Injection is a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the United States market which is approved by the U.S. Food & amp; Drug Administration (USFDA).

According to IMS Health, the Zemplar brand and generic had U.S. sales of approximately $22.5 million MAT for the most recent twelve months ending in July 2016.

Through its three businesses Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys Labs offers portfolio of products and services which includes:


  • APIs
  • Custom pharmaceutical services,
  • Generics
  • Biosimilars
  • And, differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video